Edition:
United Kingdom

Amarin Corporation PLC (AMRN.OQ)

AMRN.OQ on NASDAQ Stock Exchange Global Market

3.27USD
18 May 2018
Change (% chg)

$0.01 (+0.31%)
Prev Close
$3.26
Open
$3.25
Day's High
$3.35
Day's Low
$3.24
Volume
293,614
Avg. Vol
438,340
52-wk High
$4.59
52-wk Low
$2.67

Select another date:

Wed, May 2 2018

BRIEF-Amarin Corporation Reports Q1 GAAP Loss Per Share $0.08

* REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES UPDATE ON OPERATIONS

BRIEF-Amarin estimates net product revenue for Q1 to be about $43 mln

* AMARIN UPDATES FIRST QUARTER REVENUE GUIDANCE, REITERATES FULL YEAR GUIDANCE AND UPDATES ON REDUCE-IT CARDIOVASCULAR OUTCOMES STUDY PROGRESS AND VASCEPA PROMOTION INITIATIVES

BRIEF-Amarin's says 100 pct Mark reached on REDUCE-IT Cardiovascular Outcomes Study for Estimated Onset of Target Primary MACE

* IT CARDIOVASCULAR OUTCOMES STUDY REACHES 100% MARK FOR ESTIMATED ONSET OF TARGET PRIMARY MAJOR ADVERSE CARDIOVASCULAR EVENTS

BRIEF-Amarin Corporation Says ‍Ministry Of Public Health In Lebanon Approved Vascepa

* AMARIN CORPORATION PLC - ‍MINISTRY OF PUBLIC HEALTH IN LEBANON HAS APPROVED VASCEPA​

BRIEF-Amarin Reports Fourth Quarter Loss Of $0.08 Per Share

* AMARIN REPORTS RECORD FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES UPDATE ON OPERATIONS

BRIEF-Amarin Prices Public Offering Of American Depositary Shares

* AMARIN PRICES PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES

BRIEF-Amarin Announces Proposed Public Offering Of American Depositary Shares

* AMARIN ANNOUNCES PROPOSED PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES

BRIEF-Amarin Announces Commencement Of Vascepa Clinical Development In Mainland China

* AMARIN ANNOUNCES COMMENCEMENT OF VASCEPA CLINICAL DEVELOPMENT IN MAINLAND CHINA Source text for Eikon: Further company coverage:

BRIEF-Amarin Corp Sees Full-Year 2017 Net Product Revenue Estimated Between $177 Mln-$180 Mln​

* AMARIN PROVIDES PRELIMINARY 2017 RESULTS AND PROVIDES 2018 OUTLOOK

BRIEF-Amarin Says It Is On Track To Report Top-Line Results From REDUCE-IT Cardiovascular Outcomes Study

* AMARIN ANNOUNCES REDUCE-IT CARDIOVASCULAR OUTCOMES STUDY FINAL PATIENT VISITS TO COMMENCE IN MARCH 2018

Select another date: